GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory

BACKGROUND: Viroimmunotherapy is evolving as a strong alternative for the standard treatment of malignant gliomas. Promising results from a recent clinical trial testing the anticancer effect of Delta-24-RGD in patients with glioblastoma suggested the induction of antitumoral immunity after viral ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera-Molina, Yisel, Jiang, Hong, Fueyo, Juan, Nguyen, Teresa, Shin, Dong Ho, Youssef, Gilbert, Fan, Xuejun, Gumin, Joy, Alonso, Marta M, Phadnis, Sheetal, Lang, Frederick F, Gomez-Manzano, Candelaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777503/
https://www.ncbi.nlm.nih.gov/pubmed/31608328
http://dx.doi.org/10.1093/noajnl/vdz009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777503/
https://www.ncbi.nlm.nih.gov/pubmed/31608328
http://dx.doi.org/10.1093/noajnl/vdz009

Ejemplares similares